ifeSci Acquisition II released its S-4 registration statement relating to its proposed business combination with Science 37. The SPAC filed the form confidentially in June.
A shareholder vote date on the deal has not yet been disclosed.
Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will provide the combined company with approximately $250 million of cash (assuming no redemptions from LifeSci’s trust account). The SPAC holds approximately $80 million in trust and raised $200 million in a PIPE from institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset management arm of Mubadala Investment Company; Perceptive Advisors; PPD; Pura Vida Investments; RS Investments; RTW Investments, LP; Samsara BioCapital; and Surveyor Capital (a Citadel Company).
Founded in 2014, Science 37 provides a platform for clinical research. Read more.
